Intellia Trial to Test Gene-editing Therapy NTLA-2002 in New Zealand

Intellia Trial to Test Gene-editing Therapy NTLA-2002 in New Zealand

308687

Intellia Trial to Test Gene-editing Therapy NTLA-2002 in New Zealand

The New Zealand Medicines and Medical Devices Safety Authority has authorized Intellia Therapeutics to launch a Phase 1/2 trial testing NTLA-2002, its investigational gene-editing therapy, in adults with hereditary angioedema (HAE). According to the company, patient enrollment is expected to start by the end of the year. Data from this trial will be used to determine the best doses of NTLA-2002 for future studies, according to Intellia. “We look forward to initiating this year our…

You must be logged in to read/download the full post.